SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending due to its ramped-up AI investments and a new partnership with Nvidia focused on advancing "Physical AI," which includes integrating Nvidia’s full suite of AI development tools into Alibaba Cloud’s platform.  The community is discussing the significance of this partnership, potential growth in the Chinese tech sector, and renewed interest from major institutional investors like Cathie Wood. Some investors believe this news signals a broader resurgence for Chinese tech stocks and AI.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The community is rallying around CAW.X, emphasizing its fully circulated supply and organic, community-driven nature across multiple chains like Solana, BSC, Cronos, and Ethereum's BASE network. Discussions highlight its deflationary mechanism and partnerships as key factors.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon ($AMZN) is trending with mixed sentiment as investors digest recent news and anticipate upcoming catalysts. While some express frustration with the stock's YTD performance and cite concerns about AWS growth and an FTC trial, others view the dip as a buying opportunity ahead of a potential hardware event and the holiday season. Community members are actively debating potential price movements and speculating on the impact of various factors, including analyst ratings and technical indicators.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending as investors discuss its potential for significant revenue growth following recent acquisitions and partnerships, including a new deal with Red Lobster. Community members are highlighting the high short interest and speculating about a potential short squeeze, with some anticipating a move towards higher price targets. Bullish sentiment is fueled by expectations of AI adoption across various industries and potential partnerships with major players.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a mix of factors, including a raised price target from an analyst and momentum from a recent Air Force contract. The community is actively discussing the stock's high valuation and potential short squeeze, with some expressing concerns about a possible pullback. Despite mixed opinions on the company's long-term prospects, the stock is currently experiencing significant interest amid a broader rally in quantum computing stocks.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors discuss unusual ticker behavior and potential suppression on Stocktwits ahead of earnings. The community is speculating about ticker irregularities and a possible delisting, raising concerns about manipulation, while also highlighting QNX's growing presence across various industries and partnerships with tech giants.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron's (MU) strong earnings and guidance are driving premarket conversation, especially regarding the company's positioning in the AI sector. The community is debating whether recent gains have already priced in the positive news, while analysts are raising price targets. Some traders express concern about oversupply risks despite tight supply for DRAM.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to community excitement surrounding a potential gamma squeeze and anticipation of future purchase orders, with some viewing the recent order as validation of their technology. Discussions also highlight the company's hiring activity and partnerships related to AI and quantum data movement.  Traders are closely watching volume and key price levels, speculating on potential catalysts and a breakout.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels ($UUUU) is trending as retail chatter increases amid speculation surrounding a potential US deal, possibly tied to congressional visits to the company's plant. The community is actively discussing the potential for government contracts and the company's role in both uranium and rare earth element production. Some traders express regrets about not buying more, while others debate short-term price movements and long-term potential in the context of growing AI and energy needs.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending due to its involvement in the U.S. Navy's UNITAS 2025 maritime exercise, showcasing AI-powered capabilities. Community members are actively discussing the potential for a short squeeze and the stock's long-term growth prospects, drawing comparisons to Palantir. Bullish sentiment is fueled by high trading volume and the anticipation of further government contracts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Should You Invest in the VanEck Biotech ETF (BBH)?

ASL Strategic Value Fund is calling for shareholders of Avadel Pharmaceuticals to vote out the company’s entire board of directors.According to a letter viewed by&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/avadel-shareholder-seeks-ousting-drugmakers-entire-board-fa071ead">The Wall Street Journal</a>, ASL alleges that Avadel mishandled the launch of its key drug, Lumryz, resulting in the company missing out on hundreds of millions of dollars in potential revenue.&nbsp;The investment firm reportedly plans to vote its $15 million stake against all of Avadel’s director nominees at the company’s annual meeting scheduled for late July.The company has been involved in litigation with its main competitor in narcolepsy, Jazz Pharmaceuticals, over patent disputes.In the letter, ASL called on Avadel to issue contingent-value rights (CVRs) to shareholders, which are future payouts tied to possible legal settlements or damages.&nbsp;One of Avadel’s ongoing cases seeks damages in excess of $1 billion.ASL further reiterates its previous demand, first made in February, that Avadel hire an investment bank to explore strategic alternatives, including a potential sale of the company.In response, a spokesperson for Avadel said the board proactively engages with shareholders and that its directors have made personal investments in the company.&nbsp;The company spokesperson further noted that the company continues to focus on “unlocking the full value of Lumryz.”In May, Avadel reported better-than-expected first-quarter sales and raised full-year revenue guidance due to improving demand for Lumryz.The pressure on Avadel comes amid weak performance across the biopharma sector.&nbsp;<a href="https://stocktwits.com/symbol/XBI">The SPDR S&amp;P Biotech ETF</a> is down 9.3% over the past year, while the&nbsp;<a href="https://stocktwits.com/symbol/SPX">S&amp;P 500</a> has gained 5.2%.<a href="https://stocktwits.com/symbol/AVDL">Avadel</a> is a $900 million market cap stock that has seen its&nbsp;stock price rise by 16.4% over the past year.&nbsp;On Stocktwits, retail sentiment for Avadel was ‘neutral’ amid ‘low’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

One of Avadel’s ongoing cases seeks damages in excess of $1 billion. Representative image via Getty Images

Avadel Pharmaceuticals Under Fire? Investor Reportedly Demands Board Ouster, Sale Talks, $1B In Damages

ASL Strategic Value Fund plans to vote its $15 million stake against all Avadel board nominees at the July meeting and is pushing for contingent-value rights tied to potential legal payouts, according to a WSJ report.

Equity

Capricor Therapeutics (CAPR) said on Tuesday that the U.S. Food and Drug Administration is not eyeing an advisory committee meeting regarding approval for its Deramiocel for the treatment of Duchenne Muscular Dystrophy (DMD) associated cardiomyopathy.Capricor shares were trading 19% higher at the time of writing.The FDA indicated that an advisory committee meeting is not required at this time, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/318/capricor-therapeutics-provides-regulatory-update-on">said</a>, while adding that its application for Deramiocel approval remains under priority review.The company said in May that the FDA is considering an advisory committee meeting, dragging down investor optimism for a possible approval.The agency is expected to decide on the approval of the drug by Aug. 31. &nbsp;Company CEO Linda Marbán said that all regulatory milestones to date have proceeded as expected, and no major issues were noted at the mid-cycle review of the application.An in-person late-cycle meeting is now scheduled for mid-July.Deramiocel is Capricor’s lead cell therapy candidate for Duchenne Muscular Dystrophy, a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.On Stocktwits, retail sentiment around Capricor stayed unchanged within the ‘extremely bullish’ territory over the past 24 hours while message volume remained ‘extremely high.’<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_12_58_45_PM_png_3f23c3492d.webp" alt="CAPR's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 24, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>CAPR's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the drug getting approved early following the company’s update.<stembedurl>https://stocktwits.com/Drichman7/message/618833665</stembedurl>However, Roth Capital analyst Boobalan Pachaiyappan told investors in a research note that the FDA's intention not to require a meeting "at this time" for Deramiocel “may not necessarily be positive news.”The analyst believes a promissory advisory committee meeting would be positive, as a potential positive panel vote would put pressure on the new FDA leadership to approve deramiocel in its current form.The firm reiterates a ‘Buy’ rating and $31 price target on Capricor shares.H.C. Wainright, however, opined that even in bear case scenarios with the FDA, late-stage trial data readouts are "waiting in the wings" to further strengthen Deramiocel's overall clinical and regulatory package. The analyst believes Deramiocel's first-in-class therapeutic profile, in tandem with strong manufacturing support, will get the therapy over the finish line on expected timelines, as per TheFly.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by about 34% this year but up by about 91% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-presses-congress-to-pass-tax-bill-and-get-the-deal-done-this-week-after-iran-israel-ceasefire/chm4iPpRR3L">Trump Presses Congress To Pass Tax Bill And ‘Get The Deal Done’ This Week After Iran-Israel Ceasefire</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Capricor Therapeutics Says FDA May Not Hold Advisory Committee Meeting For DMD Therapy Approval: Stock Soars But Analyst Issues Warning

The FDA has indicated that an advisory committee meeting is not required at this time, the company said, while adding that its application for Deramiocel approval remains under priority review.

Shares of Capricor Therapeutics (CAPR) tumbled 16% on Friday morning following reports that Nicole Verdun, director of the office that reviews cell and gene therapies at the Food and Drug Administration, and her deputy have been placed on administrative leave.Stat News on Wednesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.statnews.com/2025/06/18/top-gene-therapy-regulator-forced-out-at-fda/">reported</a>, citing a recording of a meeting, that Verdun and her deputy Rachael Anatol were escorted out of the agency, sending CAPR shares down on Friday morning. Verdun was the FDA's key overseer of Capricor's application for approval of its Deramiocel drug.Capricor on Friday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/317/capricor-therapeutics-announces-positive-4-year-data-from">announced</a> positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.Deramiocel is Capricor’s lead cell therapy candidate for Duchenne Muscular Dystrophy, a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.Last month, Capricor announced after a mid-cycle review meeting that the FDA is on track to decide on its application by the end of August, the deadline. No significant issues or major deficiencies were noted at the time of the mid-cycle review.A late-cycle meeting is now planned for mid-July.Capricor on Friday said that after four years of continuous treatment, Deramiocel-treated patients showed preservation of cardiac function, including Left Ventricular Ejection Fraction, which is a measurement of how well the left ventricle, the heart's main pumping chamber, is working.Treatment also continued to slow the progression of skeletal muscle disease, the company said, while adding that the findings suggest that extended treatment with Deramiocel may help attenuate the progression of DMD over time.CEO Linda Marbán said that the company is moving toward potential approval of the therapy, with several key regulatory steps now completed.“Our continued dialogue with the FDA remains on track with no evidence of any delays,” she said.On Stocktwits, retail sentiment around Capricor jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_20_at_10_35_01_AM_png_6034c09f71.webp" alt="CAPR's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 20, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>CAPR's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that, although things don't look good, the new 4-year data from the study could ‘change things’ for Capricor.<stembedurl>https://stocktwits.com/MrMarB/message/618459744</stembedurl><a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by 33% this year but has more than doubled its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/uniswap-uni-fair-gas/chlxZJTRRPA">Uniswap Makes Fees Someone Else’s Problem</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data

Capricor on Friday announced positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.

Shares of Capricor Therapeutics (CAPR) were in the spotlight on Wednesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/11/3097631/0/en/Capricor-Therapeutics-Announces-Key-Regulatory-Updates-for-its-Duchenne-Muscular-Dystrophy-Program.html">announced</a> the completion of the U.S. Food and Drug Administration’s (FDA) Pre-License Inspection (PLI) of its San Diego manufacturing facility for Deramiocel.Deramiocel is the company’s lead cell therapy candidate. It is under FDA review for potential approval in the treatment of Duchenne Muscular Dystrophy (DMD), a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles.No material changes are required to the manufacturing process or the facility following the inspection, the company said.While the FDA made observations, they were primarily related to routine quality systems and documentation practices, it added.Capricor expressed confidence that the facility will meet the necessary requirements to support product licensure and commercial launch, pending approval.Capricor is now looking to present evidence in support of an approval for Deramiocel in an upcoming advisory committee meeting. While the FDA has expressed intent to hold the meeting on July 30, it is yet to be confirmed by the agency, Capricor said.Last month, the company announced after a mid-cycle review meeting that the FDA is on track to decide on its application by the end of August, the deadline. No significant issues or major deficiencies were noted at the time of the mid-cycle review.A late-cycle meeting is also planned for mid-July.On Stocktwits, retail sentiment around Capricor stayed unchanged within the ‘bullish’ territory over the past 24 hours while message volume remained ‘high’.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_11_at_11_38_14_AM_png_cc62744706.webp" alt="CAPR's Sentiment Meter and Message Volume as of 11:38 a.m. ET on Jun 11, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>CAPR's Sentiment Meter and Message Volume as of 11:38 a.m. ET on Jun 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about Deramiocel, opining that the technology has “unimaginable potential.”<stembedurl>https://stocktwits.com/snowboy/message/617558955</stembedurl><a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by about 10% this year but up by about 143% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-inks-812-million-deal-wth-deep-apple-therapeutics/chlaHHKRbCH">Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’

Capricor expressed confidence that the facility will meet the necessary requirements to support product licensure and commercial launch, pending approval.

SPDR Series Trust - SPDR Biotech ETF

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

XBI
SPDR S&P Biotech ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XBI News

XBI SPDR S&P Biotech ETF